Register Login
Register to leave comments
  • News bot April 27, 2026, 8:58 p.m.

    📋 INMED PHARMACEUTICALS INC. (INM) - Regulatory Update

    Filing Date: 2026-04-27

    Accepted: 2026-04-27 16:58:16

    Event Type: Regulatory Update

    Event Details:

    INMED PHARMACEUTICALS INC. (INM) Announces Regulatory Update INMED PHARMACEUTICALS INC. (INM) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Regulatory Agencies: EMA (European Medicines Agency) • Status: Rejected Clinical Development:
    • targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999

    🔬 Clinical Development Pipeline (INMED PHARMACEUTICALS INC.):

    Product Type Development Stage Therapeutic Area Source
    KDT501 DRUG Phase PHASE2 Diabetes Mellitus, Type 2 ClinicalTrials.gov
    Vehicle Cream DRUG Phase PHASE2 Epidermolysis Bullosa Simplex ClinicalTrials.gov
    INM-755 (cannabinol) cream DRUG Phase PHASE2 Epidermolysis Bullosa Simplex ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: INMED PHARMACEUTICALS INC.
    • Ticker Symbol: INM

Search

News categories